| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $99,747 | 1 | 13 |
Sells | $2,430,818 | 7 | 87 |
| Sarraf Pasha | director | 1 | $99,747 | 0 | $0 | $99,747 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer | 0 | $0 | 2 | $201,413 | $-201,413 |
| Ray Sumita | Chief Legal Compliance Officer | 0 | $0 | 2 | $317,352 | $-317,352 |
| Lin Shao-Lee | Chief Executive Officer | 0 | $0 | 3 | $1.91M | $-1.91M |
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the human immune system to address a spectrum of severe conditions, such as various cancers, chronic infectious diseases, and autoimmune disorders. The company's leading investigational therapeutic is CUE-101, a specialized fusion protein biologic. This candidate is currently advancing through Phase 1b clinical trials, engineered to specifically identify and activate antigen-specific …
Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $99,747 and sold $2.43M worth of Cue Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $984,392 and sold $1.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Sarraf Pasha (director) — $99,747.
The last purchase of 323,857 shares for transaction amount of $99,747 was made by Sarraf Pasha (director) on 2025‑12‑30.
| 2026-10-12 | Sale | Lin Shao-Lee | Chief Executive Officer | 11,087 0.1958% | $27.55 | $305,490 | -23.69% | |
| 2026-10-12 | Sale | Ray Sumita | Chief Legal Compliance Officer | 1,844 0.0331% | $28.05 | $51,724 | -23.69% | |
| 2026-10-12 | Sale | Meluzio Michael Vincent | VP, Prin. Accounting Officer | 1,144 0.0206% | $28.05 | $32,089 | -23.69% | |
| 2026-08-13 | Sale | Lin Shao-Lee | Chief Executive Officer | 18,258 0.6398% | $28.62 | $522,573 | -17.31% | |
| 2026-08-13 | Sale | Ray Sumita | Chief Legal Compliance Officer | 8,829 0.1348% | $30.09 | $265,628 | -17.31% | |
| 2026-08-13 | Sale | Meluzio Michael Vincent | VP, Prin. Accounting Officer | 5,628 0.0859% | $30.09 | $169,324 | -17.31% | |
| 2026-08-12 | Sale | Lin Shao-Lee | Chief Executive Officer | 40,000 1.356% | $27.10 | $1.08M | -15.24% | |
| 2025-12-30 | Sarraf Pasha | director | 323,857 0.4184% | $0.31 | $99,747 | +143.83% | ||
| 2024-12-16 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 30,000 0.0473% | $1.03 | $30,900 | -23.33% | ||
| 2023-08-25 | Suri Anish | PRESIDENT AND CSO | 4,000 0.0088% | $2.76 | $11,040 | -27.78% | ||
| 2023-08-14 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 3,000 0.0065% | $2.86 | $8,580 | -33.06% | ||
| 2023-03-23 | Sale | Kiener Peter A | director | 9,325 0.0208% | $3.28 | $30,586 | -14.24% | |
| 2022-05-27 | Morich Frank | 28,000 0.0769% | $3.75 | $105,000 | -19.17% | |||
| 2022-05-23 | Fletcher Aaron G.L. | 55,000 0.1455% | $3.34 | $183,700 | -12.61% | |||
| 2022-03-31 | Fletcher Aaron G.L. | 735,000 2.0277% | $4.76 | $3.5M | -36.07% | |||
| 2021-11-16 | Sale | Kiener Peter A | director | 1,361 0.0046% | $18.02 | $24,525 | -77.86% | |
| 2021-11-15 | Sale | Suri Anish | President and CSO | 8,000 0.0257% | $18.05 | $144,400 | -78.74% | |
| 2021-11-15 | Sale | Kiener Peter A | director | 18,815 0.0599% | $17.92 | $337,165 | -78.74% | |
| 2021-11-11 | Sale | Suri Anish | President and CSO | 20,000 0.0634% | $15.07 | $301,354 | -74.37% | |
| 2021-10-01 | Sale | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 1,251 0.0039% | $14.21 | $17,783 | -66.60% |
| Sarraf Pasha | director | 323857 4.4581% | $6.76M | 1 | 0 | |
| Fletcher Aaron G.L. | 940000 12.9398% | $19.61M | 4 | 0 | <0.0001% | |
| Gray Cameron | director | 677500 9.3263% | $14.13M | 2 | 0 | <0.0001% |
| PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 164578 2.2655% | $3.43M | 7 | 0 | <0.0001% |
| Suri Anish | PRESIDENT AND CSO | 135638 1.8672% | $2.83M | 2 | 6 | +22.99% |
| DIGIANDOMENICO ANTHONY | director | 57000 0.7846% | $1.19M | 5 | 0 | +68.36% |
| Morich Frank | 28000 0.3854% | $584,080.00 | 1 | 0 | <0.0001% | |
| Sandercock Colin | SVP, General Counsel and Sec | 17125 0.2357% | $357,227.50 | 3 | 3 | +52.57% |
| Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 10472 0.1442% | $218,445.92 | 1 | 1 | <0.0001% |
| Pienta Kenneth | Chief Medical Officer | 2000 0.0275% | $41,720.00 | 2 | 5 | <0.0001% |
| MARLETT CHRISTOPHER A | director | 0 0% | $0 | 9 | 6 | +65.21% |
$16,280,851 | 76 | 1.48% | $118.27M | |
Cue Biopharma, Inc. (CUE) | $6,788,859 | 35 | 26.72% | $151.54M |
$7,147,964 | 34 | 24.77% | $166.39M | |
$47,438,336 | 33 | -21.38% | $122.37M | |
$38,621,826 | 31 | 1.43% | $157.74M |
| Increased Positions | 14 | +21.21% | 4M | +21.42% |
| Decreased Positions | 22 | -33.33% | 538,440 | -2.99% |
| New Positions | 7 | New | 2M | New |
| Sold Out Positions | 11 | Sold Out | 191,839 | Sold Out |
| Total Postitions | 58 | -12.12% | 21M | +18.43% |
| Bleichroeder Lp | $2,298.00 | 7.49% | 6.82M | 0 | 0% | 2025-09-30 |
| Gc Wealth Management Ria, Llc | $1,156.00 | 3.77% | 3.43M | +100,000 | +3% | 2025-09-30 |
| Vanguard Group Inc | $1,024.00 | 3.34% | 3.04M | -148,024 | -4.64% | 2025-09-30 |
| Geode Capital Management, Llc | $270.00 | 0.88% | 800,768 | +108,595 | +15.69% | 2025-09-30 |
| Boothbay Fund Management, Llc | $206.00 | 0.67% | 610,964 | +610,964 | New | 2025-09-30 |
| Robertson Stephens Wealth Management, Llc | $161.00 | 0.53% | 478,500 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $151.00 | 0.49% | 449,162 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $109.00 | 0.36% | 324,521 | -63 | -0.02% | 2025-09-30 |
| Advisory Research Inc | $87.00 | 0.28% | 257,225 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $77.00 | 0.25% | 227,064 | +93,600 | +70.13% | 2025-09-30 |